CR20200416A - Nuevos compuestos heterocíclicos - Google Patents
Nuevos compuestos heterocíclicosInfo
- Publication number
- CR20200416A CR20200416A CR20200416A CR20200416A CR20200416A CR 20200416 A CR20200416 A CR 20200416A CR 20200416 A CR20200416 A CR 20200416A CR 20200416 A CR20200416 A CR 20200416A CR 20200416 A CR20200416 A CR 20200416A
- Authority
- CR
- Costa Rica
- Prior art keywords
- magl
- oxazine
- inhibitors
- monoacylglycerol lipase
- sup
- Prior art date
Links
- BCHZICNRHXRCHY-UHFFFAOYSA-N 2h-oxazine Chemical compound N1OC=CC=C1 BCHZICNRHXRCHY-UHFFFAOYSA-N 0.000 title 1
- 102000005398 Monoacylglycerol Lipase Human genes 0.000 title 1
- 108020002334 Monoacylglycerol lipase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
<p>La invención proporciona nuevos compuestos heterocíclicos que presentan la fórmula general (Ic), en la que A, L, X, m, n y R<sup>20</sup> a R<sup>23</sup> son tal como se describe en la presente memoria, composiciones que incluyen los compuestos, procedimientos de preparación de los compuestos y métodos de utilización de los compuestos. </p>
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18163273 | 2018-03-22 | ||
| CN2019075372 | 2019-02-18 | ||
| PCT/EP2019/057174 WO2019180185A1 (en) | 2018-03-22 | 2019-03-22 | Oxazine monoacylglycerol lipase (magl) inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20200416A true CR20200416A (es) | 2020-10-26 |
Family
ID=65818027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20200416A CR20200416A (es) | 2018-03-22 | 2019-03-22 | Nuevos compuestos heterocíclicos |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US20210107920A1 (es) |
| EP (1) | EP3768684B1 (es) |
| JP (1) | JP7308220B2 (es) |
| KR (1) | KR20200136425A (es) |
| CN (1) | CN111936503B (es) |
| AU (1) | AU2019238381B2 (es) |
| BR (1) | BR112020014992A2 (es) |
| CA (1) | CA3089443A1 (es) |
| CL (1) | CL2020002423A1 (es) |
| CO (1) | CO2020009567A2 (es) |
| CR (1) | CR20200416A (es) |
| DK (1) | DK3768684T3 (es) |
| ES (1) | ES2942319T3 (es) |
| FI (1) | FI3768684T3 (es) |
| HR (1) | HRP20230388T1 (es) |
| HU (1) | HUE061584T2 (es) |
| IL (1) | IL276031B2 (es) |
| LT (1) | LT3768684T (es) |
| MX (1) | MX2020008894A (es) |
| PE (1) | PE20201185A1 (es) |
| PH (1) | PH12020500661A1 (es) |
| PL (1) | PL3768684T3 (es) |
| RS (1) | RS64156B1 (es) |
| SG (1) | SG11202007608UA (es) |
| SI (1) | SI3768684T1 (es) |
| TW (1) | TWI818967B (es) |
| WO (1) | WO2019180185A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
| CN111386269A (zh) | 2017-11-28 | 2020-07-07 | 豪夫迈·罗氏有限公司 | 新型杂环化合物 |
| EP3737680A1 (en) | 2018-01-08 | 2020-11-18 | F. Hoffmann-La Roche AG | Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors |
| EP3837263B1 (en) | 2018-08-13 | 2024-07-03 | F. Hoffmann-La Roche AG | New heterocyclic compounds as monoacylglycerol lipase inhibitors |
| EP3883936B1 (en) | 2018-11-22 | 2023-07-12 | F. Hoffmann-La Roche AG | New heterocyclic compounds |
| US20210094971A1 (en) * | 2019-09-09 | 2021-04-01 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
| US11814375B2 (en) * | 2019-09-12 | 2023-11-14 | Hoffmann-La Roche Inc. | Heterocyclic compounds |
| MX2022003023A (es) * | 2019-09-23 | 2022-04-07 | Hoffmann La Roche | Compuestos heterociclicos. |
| CA3152213A1 (en) * | 2019-09-24 | 2021-04-01 | F. Hoffmann-La Roche Ag | New heterocyclic monoacylglycerol lipase (magl) inhibitors |
| AR120029A1 (es) * | 2019-09-24 | 2022-01-26 | Hoffmann La Roche | Compuestos heterocíclicos |
| EP4034602A1 (en) * | 2019-09-24 | 2022-08-03 | F. Hoffmann-La Roche AG | Fluorescent probes for monoacylglycerol lipase (magl) |
| MX2023002224A (es) | 2020-09-03 | 2023-03-15 | Hoffmann La Roche | Compuestos heterociclicos. |
| CA3234429A1 (en) * | 2021-10-15 | 2023-04-20 | Luc Farmer | Ras inhibitors, compositions and methods of use thereof |
| CA3242372A1 (en) | 2021-12-29 | 2023-07-06 | Psy Therapeutics, Inc. | Inhibiting monoacylglycerol lipase (magl) |
| EP4543870A1 (en) * | 2022-06-24 | 2025-04-30 | F. Hoffmann-La Roche AG | New heterocyclic-carbonyl-cyclic compounds as magl inhibitors |
| TW202415651A (zh) | 2022-07-29 | 2024-04-16 | 日商住友製藥股份有限公司 | 含氮飽和雜環衍生物 |
| CN119894887A (zh) * | 2022-09-20 | 2025-04-25 | 豪夫迈·罗氏有限公司 | 用于magl的荧光探针 |
| EP4665718A1 (en) * | 2023-02-13 | 2025-12-24 | Apogee Pharmaceuticals, Inc. | Small molecules as monoacylglycerol lipase (magl) inhibitors, compositions and use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7579495B2 (en) | 2003-12-19 | 2009-08-25 | Momentive Performance Materials Inc. | Active-releasing cyclic siloxanes |
| ATE450525T1 (de) | 2005-06-20 | 2009-12-15 | Schering Corp | Kohlenstoffgebundene substituierte piperidine und derivate daraus als histamin-h3-antagonisten |
| AU2007217040A1 (en) | 2006-02-17 | 2007-08-30 | Memory Pharmaceuticals Corporation | Compounds having 5-HT6 receptor affinity |
| WO2007117557A2 (en) | 2006-04-05 | 2007-10-18 | Vitae Pharmaceuticals, Inc. | Diaminopropanol renin inhibitors |
| WO2011059118A1 (ko) | 2009-11-10 | 2011-05-19 | Kim Hyun Jeen | 후각인지능력 검사 시스템 |
| US9493451B2 (en) | 2011-05-16 | 2016-11-15 | Bionomics Limited | Amine derivatives as potassium channel blockers |
| ES2793148T3 (es) * | 2012-01-06 | 2020-11-13 | Lundbeck La Jolla Research Center Inc | Compuestos de carbamato y métodos para fabricarlos y usarlos |
| GB201209587D0 (en) | 2012-05-30 | 2012-07-11 | Takeda Pharmaceutical | Therapeutic compounds |
| WO2016109501A1 (en) | 2014-12-30 | 2016-07-07 | Karos Pharmaceuticals, Inc. | Amide compounds as tryptophan hydroxylase inhibitors |
| EP3294729A1 (en) | 2015-05-13 | 2018-03-21 | Selvita S.A. | Substituted quinoxaline derivatives |
| AU2016264958B2 (en) | 2015-05-21 | 2020-10-29 | Glaxosmithkline Intellectual Property Development Limited | Benzoimidazole derivatives as PAD4 inhibitors |
| US10919875B2 (en) | 2015-06-18 | 2021-02-16 | 89Bio Ltd | Substituted 4-benzyl and 4-benzoyl piperidine derivatives |
| CN105198903B (zh) * | 2015-11-09 | 2016-08-24 | 代先慧 | 一种治疗急性上呼吸道感染的药物组合物 |
| JP6832342B2 (ja) * | 2016-03-31 | 2021-02-24 | 武田薬品工業株式会社 | 複素環化合物 |
-
2019
- 2019-03-22 HR HRP20230388TT patent/HRP20230388T1/hr unknown
- 2019-03-22 DK DK19711920.9T patent/DK3768684T3/da active
- 2019-03-22 MX MX2020008894A patent/MX2020008894A/es unknown
- 2019-03-22 LT LTEPPCT/EP2019/057174T patent/LT3768684T/lt unknown
- 2019-03-22 JP JP2020548747A patent/JP7308220B2/ja active Active
- 2019-03-22 CR CR20200416A patent/CR20200416A/es unknown
- 2019-03-22 PE PE2020001119A patent/PE20201185A1/es unknown
- 2019-03-22 BR BR112020014992-6A patent/BR112020014992A2/pt not_active Application Discontinuation
- 2019-03-22 TW TW108110005A patent/TWI818967B/zh not_active IP Right Cessation
- 2019-03-22 RS RS20230303A patent/RS64156B1/sr unknown
- 2019-03-22 WO PCT/EP2019/057174 patent/WO2019180185A1/en not_active Ceased
- 2019-03-22 HU HUE19711920A patent/HUE061584T2/hu unknown
- 2019-03-22 KR KR1020207029587A patent/KR20200136425A/ko active Pending
- 2019-03-22 EP EP19711920.9A patent/EP3768684B1/en active Active
- 2019-03-22 AU AU2019238381A patent/AU2019238381B2/en not_active Ceased
- 2019-03-22 CA CA3089443A patent/CA3089443A1/en active Pending
- 2019-03-22 SI SI201930519T patent/SI3768684T1/sl unknown
- 2019-03-22 PL PL19711920.9T patent/PL3768684T3/pl unknown
- 2019-03-22 ES ES19711920T patent/ES2942319T3/es active Active
- 2019-03-22 CN CN201980018255.1A patent/CN111936503B/zh active Active
- 2019-03-22 FI FIEP19711920.9T patent/FI3768684T3/fi active
- 2019-03-22 SG SG11202007608UA patent/SG11202007608UA/en unknown
-
2020
- 2020-07-13 IL IL276031A patent/IL276031B2/en unknown
- 2020-07-31 CO CONC2020/0009567A patent/CO2020009567A2/es unknown
- 2020-09-08 PH PH12020500661A patent/PH12020500661A1/en unknown
- 2020-09-18 US US17/025,155 patent/US20210107920A1/en not_active Abandoned
- 2020-09-21 CL CL2020002423A patent/CL2020002423A1/es unknown
-
2022
- 2022-08-09 US US17/818,459 patent/US20230117324A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20200416A (es) | Nuevos compuestos heterocíclicos | |
| MX2021001433A (es) | Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa. | |
| CR20210056A (es) | Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa | |
| PH12021551167A1 (en) | New heterocyclic compounds | |
| PH12022550339A1 (en) | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors | |
| PH12022550472A1 (en) | New heterocyclic monoacylglycerol lipase (magl) inhibitors | |
| PH12022550321A1 (en) | 4,4a,5,7,8,8a-hexapyrido[4,3-b][1,4]oxazin-3-one compounds as magl inhibitors | |
| MX2023012477A (es) | Compuestos heterociclicos. | |
| PH12022550433A1 (en) | Heterocyclic compounds | |
| PH12013501489A1 (en) | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | |
| MX381728B (es) | Compuestos heterocíclicos útiles como inhibidores dobles de autotaxina (atx)/anhidrasa carbónica (ca). | |
| PH12019500664A1 (en) | New isoxazolyl ether derivatives as gaba a alpha5 pam | |
| PH12022550471A1 (en) | Heterocyclic compounds | |
| CR20220004A (es) | Nuevos compuestos heterocíclicos | |
| MX2023002224A (es) | Compuestos heterociclicos. | |
| PH12020500674A1 (en) | New isoxazolyl ether derivatives as gaba a alpha5 pam | |
| PH12021550320A1 (en) | Bicyclic heteroaryl derivatives |